NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE)
$47.08 -4.53 (-8.7774%)
Analysed NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) News Sources
European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial
31-07-2026
yahoo.com
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
31-07-2026
247wallst.com
Novo Nordisk’s Heart Drug Suffers a Major Setback. What It Means for the Stock.
31-07-2026
yahoo.com
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
31-07-2026
fool.com
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
31-07-2026
yahoo.com
NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial
31-07-2026
barchart.com
Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said.
31-07-2026
yahoo.com
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?
31-07-2026
fool.com
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
31-07-2026
stocktwits.com
NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court
01-08-2026
stocktwits.com
What is the current price of NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE)?
The current price of NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) is $47.08.
NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) absolute price change since previous trading day?
The absolute price change of NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) since the previous trading day is $-4.53.
NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) percentage price change since previous trading day?
The percentage price change of NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) since the previous trading day is -8.7774%.
What is the most recent average sentiment score for NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE)?
The most recent average sentiment score for NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) is 27 out of 100.
What is the most recent average sentiment for NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE)?
The most recent sentiment for NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE) is .
SEC-8K** Filing Available For NOVO-NORDISK A/S-SPONS ADR (NVO:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.